Published in J Med Chem on February 01, 1983
Semiautomated radiosynthesis and biological evaluation of [18F]FEAU: a novel PET imaging agent for HSV1-tk/sr39tk reporter gene expression. Mol Imaging Biol (2007) 1.21
Fluorinated Nucleosides: Synthesis and Biological Implication. J Fluor Chem (2008) 1.01
Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2. Antimicrob Agents Chemother (1986) 0.91
Antirhinovirus activity of purine nucleoside analogs. Antimicrob Agents Chemother (1986) 0.80
Synthesis of DNA oligos containing 2'-deoxy-2'-fluoro-D-arabinofuranosyl-5-carboxylcytosine as hTDG inhibitor. Tetrahedron (2012) 0.77
Synthesis and antiviral evaluation of 2',2',3',3'-tetrafluoro nucleoside analogs. Tetrahedron Lett (2017) 0.75
An investigation on stereospecific fluorination at the 2'-arabino-position of a pyrimidine nucleoside: radiosynthesis of 2'-deoxy-2'-[(18)F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil. Tetrahedron (2012) 0.75
Synthesis and spectral characterization of environmentally responsive fluorescent deoxycytidine analogs. Artif DNA PNA XNA (2014) 0.75
A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med (1989) 10.98
Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med (1984) 6.11
Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med (1977) 5.86
PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol (1997) 5.76
Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med (1981) 5.44
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med (1989) 4.72
Transmission of the human immunodeficiency virus. N Engl J Med (1987) 4.17
Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med (1983) 3.67
Setting events in applied behavior analysis: Toward a conceptual and methodological expansion. J Appl Behav Anal (1981) 3.49
Genetics of natural resistance to herpesvirus infections in mice. Nature (1975) 3.18
Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med (2000) 3.15
The family Herpesviridae: an update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. Arch Virol (1992) 3.09
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides. J Med Chem (1979) 2.80
Intravenous drug abusers and the acquired immunodeficiency syndrome (AIDS). Demographic, drug use, and needle-sharing patterns. Arch Intern Med (1985) 2.62
Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis (2001) 2.51
Knowledge of HIV antibody status and decisions to continue or terminate pregnancy among intravenous drug users. JAMA (1989) 2.41
Lack of transmission of HTLV-III/LAV infection to household contacts of patients with AIDS or AIDS-related complex with oral candidiasis. N Engl J Med (1986) 2.40
Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med (1992) 2.36
Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases. Antimicrob Agents Chemother (1981) 2.34
The deamination of cytidine and cytosine by acidic buffer solutions. Mutagenic implications. Biochemistry (1966) 2.30
Survival differences in patients with AIDS. J Acquir Immune Defic Syndr (1991) 2.23
Methods for conducting sensitivity analysis of trials with potentially nonignorable competing causes of censoring. Biometrics (2001) 2.21
Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoattraction. Cell (2001) 2.20
High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA (1992) 2.19
Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother (1992) 2.17
Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem (1992) 2.13
Streptococcus bovis septicemia and carcinoma of the colon. Ann Intern Med (1979) 2.06
2'-fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent. Antimicrob Agents Chemother (1980) 1.96
Natural killing of herpes simplex virus type 1-infected target cells: normal human responses and influence of antiviral antibody. Infect Immun (1979) 1.94
Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Ann Intern Med (1993) 1.92
Kinetic mechanism of damage site recognition and uracil flipping by Escherichia coli uracil DNA glycosylase. Biochemistry (1999) 1.92
A novel lysine-substituted nucleoside in the first position of the anticodon of minor isoleucine tRNA from Escherichia coli. J Biol Chem (1988) 1.85
Association of renal allograft rejection with virus infections. Am J Med (1974) 1.83
Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob Agents Chemother (1987) 1.82
Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis (2001) 1.77
Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS (1988) 1.75
A rapid and simple method for preparation of adenovirus DNA from infected cells. Microbiol Immunol (1983) 1.71
Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Study Group. Clin Infect Dis (1999) 1.69
Characterization of a new primary human pancreatic tumor line. Cancer Invest (1986) 1.67
Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro. Antimicrob Agents Chemother (1986) 1.66
Prospective study of human immunodeficiency virus infection and pregnancy outcomes in intravenous drug users. JAMA (1989) 1.63
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (2000) 1.60
5-Fluorocytosine in DNA is a mechanism-based inhibitor of HhaI methylase. Biochemistry (1988) 1.57
Factors associated with unrecognized HIV-1 infection in an inner-city emergency department. Ann Emerg Med (1996) 1.54
A prospective study of HIV disease progression in female and male drug users. AIDS (1999) 1.54
Rigid contact lens fitting relationships in keratoconus. Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study Group. Optom Vis Sci (1999) 1.53
Molecular cloning and structure of the gene for 7 beta-(4-carboxybutanamido)cephalosporanic acid acylase from a Pseudomonas strain. J Bacteriol (1985) 1.52
An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis (1996) 1.51
Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol (2001) 1.51
Cell-mediated immune responses in recurrent herpesvirus infections. I. Lymphocyte proliferation assay. J Immunol (1977) 1.51
Targeted gene knockout mediated by triple helix forming oligonucleotides. Nat Genet (1998) 1.51
Lack of association of induration size with HIV infection among drug users reacting to tuberculin. Am J Respir Crit Care Med (1996) 1.47
Toward an ecosocial view of health. Int J Health Serv (1999) 1.47
Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. J Am Acad Dermatol (1987) 1.47
Accuracy of magnetic resonance imaging of inguinofemoral lymph nodes in vulval cancer. Int J Gynecol Cancer (2006) 1.47
Isolation of a virus from the lungs of Montana sheep affected with progressive pneumonia. Virology (1968) 1.46
Antileukemic effects of pseudoisocytidine, a new synthetic pyrimidine C-nucleoside. Cancer Res (1976) 1.44
Evaluation of static bone cavities with CT and MRI. Dentomaxillofac Radiol (2003) 1.42
Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother (1996) 1.42
Highly expressed cytoplasmic FcεRIβ in human mast cells functions as a negative regulator of the FcRγ-mediated cell activation signal. Clin Exp Allergy (2014) 1.40
Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother (1992) 1.40
Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health (1995) 1.40
High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol (1991) 1.39
Neuroleptic dosage in psychiatric outpatients. Psychiatr Serv (1996) 1.39
Shape memory in hydrogels. Nature (1995) 1.38
Histology and prevalence of ovarian tumours in postmenopausal women: is follow-up required in all cases? J Obstet Gynaecol (2012) 1.38
Heterogeneity of human NK cells: comparison of effectors that lyse HSV-1-infected fibroblasts and K562 erythroleukemia targets. J Immunol (1983) 1.37
Incidence of aneurysms in Takayasu's arteritis. Angiology (1991) 1.36
Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (1992) 1.36
Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus. J Acquir Immune Defic Syndr (1990) 1.36
Cytomegalovirus: Clinical virological correlations in renal transplant recipients. Ann Surg (1974) 1.34
Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV). J Med Chem (1988) 1.33
Solitary toy play and time out: a family treatment package for children with aggressive and oppositional behavior. J Appl Behav Anal (1980) 1.33
1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. J Med Chem (1993) 1.31
1,000 consecutive ultrasounds for blunt abdominal trauma. J Trauma (1996) 1.31
Facilitation or attenuation of mixed leukocyte culture responsiveness by adherent cells. Nature (1976) 1.31
Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds. Antimicrob Agents Chemother (1991) 1.30
Antibiotic activity in vitro against methicillin-resistant Staphylococcus epidermidis and therapy of an experimental infection. Antimicrob Agents Chemother (1979) 1.30
Heteronuclear NMR and crystallographic studies of wild-type and H187Q Escherichia coli uracil DNA glycosylase: electrophilic catalysis of uracil expulsion by a neutral histidine 187. Biochemistry (1999) 1.30
Peer social initiations and the modification of social withdrawal: a review and future perspective. J Pediatr Psychol (1981) 1.30
The treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med (1985) 1.29
Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A (1996) 1.28
Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care (1991) 1.28
Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology (1998) 1.26
3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. AIDS Res Hum Retroviruses (1990) 1.24
Incorporation of metabolites of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. Biochem Pharmacol (1982) 1.24
High-level transient expression of influenza virus proteins from a series of SV40 late and early replacement vectors. Gene (1988) 1.24
Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob Agents Chemother (1992) 1.24